Small molecule (Molecular glue degrader) · Degrader of IKZF2 (Helios) (IKZF2) · developed by Novartis Pharmaceuticals
DKY709 is a low molecular weight degrader of IKZF2 (Helios), a zinc finger transcription factor expressed on most regulatory T-cells. It binds the E3 ubiquitin ligase substrate receptor and brings IKZF2 to it for ubiquitination and proteasomal degradation, which can activate T-lymphocytes. It is being studied in non-small-cell lung carcinoma, melanoma, nasopharyngeal carcinoma, microsatellite stable colorectal cancer, and triple negative breast cancer.
Summary written with AI from the sources listed at the end of this page.
Carcinoma, Non-Small-Cell LungMelanomaMicrosatellite Stable Colorectal CancerNasopharyngeal CarcinomaTriple Negative Breast Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →